References
1. Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sex Transm Dis . May 2019;46(5):304-311. doi:10.1097/olq.0000000000000972
2. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med . Dec 28 1995;333(26):1737-42. doi:10.1056/nejm199512283332604
3. Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C, Pearson J. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. Bmj . Jan 29 1994;308(6924):295-8. doi:10.1136/bmj.308.6924.295
4. Sewankambo N, Gray RH, Wawer MJ, et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis.Lancet . Aug 23 1997;350(9077):546-50. doi:10.1016/s0140-6736(97)01063-5
5. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis - striving for long-term cure. BMC Infect Dis . Jul 29 2015;15:292. doi:10.1186/s12879-015-1027-4
6. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep . Jun 5 2015;64(Rr-03):1-137.
7. Bradshaw CS, Sobel JD. Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. J Infect Dis . Aug 15 2016;214 Suppl 1(Suppl 1):S14-20. doi:10.1093/infdis/jiw159
8. Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol . Nov 2005;106(5 Pt 1):1013-23. doi:10.1097/01.AOG.0000183594.45524.d2
9. Muzny CA, Schwebke JR. Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections. Clin Infect Dis . Aug 15 2015;61(4):601-6. doi:10.1093/cid/civ353
10. Machado D, Castro J, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, Cerca N. Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions. Front Microbiol . 2015;6:1528. doi:10.3389/fmicb.2015.01528
11. Donders GG, Zodzika J, Rezeberga D. Treatment of bacterial vaginosis: what we have and what we miss. Expert Opin Pharmacother . Apr 2014;15(5):645-57. doi:10.1517/14656566.2014.881800
12. Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis . Jan 15 2007;44(2):213-9. doi:10.1086/509577
13. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis . Jun 1 2006;193(11):1478-86. doi:10.1086/503780
14. Ferris DG, Litaker MS, Woodward L, Mathis D, Hendrich J. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract . Nov 1995;41(5):443-9.
15. Javed A, Parvaiz F, Manzoor S. Bacterial vaginosis: An insight into the prevalence, alternative treatments regimen and it’s associated resistance patterns. Microb Pathog . Feb 2019;127:21-30. doi:10.1016/j.micpath.2018.11.046
16. Wang Z, He Y, Zheng Y. Probiotics for the Treatment of Bacterial Vaginosis: A Meta-Analysis. Int J Environ Res Public Health . Oct 12 2019;16(20)doi:10.3390/ijerph16203859
17. Tan H, Fu Y, Yang C, Ma J. Effects of metronidazole combined probiotics over metronidazole alone for the treatment of bacterial vaginosis: a meta-analysis of randomized clinical trials. Arch Gynecol Obstet . Jun 2017;295(6):1331-1339. doi:10.1007/s00404-017-4366-0
18. McCarthy TD, Karellas P, Henderson SA, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm . Jul-Aug 2005;2(4):312-8. doi:10.1021/mp050023q
19. Tyssen D, Henderson SA, Johnson A, et al. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One . Aug 23 2010;5(8):e12309. doi:10.1371/journal.pone.0012309
20. O’Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, Paull JR. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study. Sex Transm Dis . Feb 2010;37(2):100-4. doi:10.1097/OLQ.0b013e3181bc0aac
21. Cohen CR, Brown J, Moscicki AB, et al. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days. PLoS One . Jan 20 2011;6(1):e16258. doi:10.1371/journal.pone.0016258
22. Chavoustie SE, Carter BA, Waldbaum AS, et al. Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis. Eur J Obstet Gynecol Reprod Biol . Feb 2020;245:13-18. doi:10.1016/j.ejogrb.2019.11.032
23. Waldbaum AS, Schwebke JR, Paull JRA, et al. A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis. PLoS One . 2020;15(5):e0232394. doi:10.1371/journal.pone.0232394
24. Schwebke JR CB, Waldbaum AS, Agnew KJ, Paull JR, Price CF, Castellarnau A, McCloud P, Kinghorn GR. A Phase 3 Randomized, Controlled Trial of Astodrimer 1% Gel for Preventing Recurrent Bacterial Vaginosis. medRxiv. 2020. https://doi.org/10.1101/2020.08.06.20159475.
25. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.PLoS Med . Jul 21 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097
26. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med . Jan 1983;74(1):14-22. doi:10.1016/0002-9343(83)91112-9
27. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.Bmj . Oct 18 2011;343:d5928. doi:10.1136/bmj.d5928
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj . Sep 6 2003;327(7414):557-60. doi:10.1136/bmj.327.7414.557
29. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj . Sep 13 1997;315(7109):629-34. doi:10.1136/bmj.315.7109.629
30. Marrazzo JM, Martin DH, Watts DH, et al. Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis . Dec 2010;37(12):732-44. doi:10.1097/OLQ.0b013e3181fbbc95
31. Marrazzo JM, Dombrowski JC, Wierzbicki MR, et al. Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. Clin Infect Dis . Feb 15 2019;68(5):803-809. doi:10.1093/cid/ciy554
32. Schwebke JR, Marrazzo J, Beelen AP, Sobel JD. A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis. Sex Transm Dis . Jul 2015;42(7):376-81. doi:10.1097/olq.0000000000000300
33. Schwebke JR, Morgan FG, Jr., Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol . Dec 2017;217(6):678.e1-678.e9. doi:10.1016/j.ajog.2017.08.017
34. Chavoustie SE, Jacobs M, Reisman HA, et al. Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose-ranging study.J Low Genit Tract Dis . Apr 2015;19(2):129-34. doi:10.1097/lgt.0000000000000062
35. Easmon CS, Hay PE, Ison CA. Bacterial vaginosis: a diagnostic approach. Genitourin Med . Apr 1992;68(2):134-8. doi:10.1136/sti.68.2.134
36. Bilardi JE, Walker S, Temple-Smith M, et al. The burden of bacterial vaginosis: women’s experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One . 2013;8(9):e74378. doi:10.1371/journal.pone.0074378
37. Donders GG, Guaschino S, Peters K, Tacchi R, Lauro V. A multicenter, double-blind, randomized, placebo-controlled study of rifaximin for the treatment of bacterial vaginosis. Int J Gynaecol Obstet . Feb 2013;120(2):131-6. doi:10.1016/j.ijgo.2012.08.022
38. Abu-Rustum NR, Zhou Q, Iasonos A, et al. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? Int J Gynecol Cancer . Apr 2011;21(3):511-6. doi:10.1097/IGC.0b013e31820cc305
39. Machado A, Cerca N. Influence of Biofilm Formation by Gardnerella vaginalis and Other Anaerobes on Bacterial Vaginosis. J Infect Dis . Dec 15 2015;212(12):1856-61. doi:10.1093/infdis/jiv338
40. Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol . Jan 2008;198(1):97.e1-6. doi:10.1016/j.ajog.2007.06.039